DOP2017000213A - Derivados de bencimidazol como inhibidores de bromodominio - Google Patents
Derivados de bencimidazol como inhibidores de bromodominioInfo
- Publication number
- DOP2017000213A DOP2017000213A DO2017000213A DO2017000213A DOP2017000213A DO P2017000213 A DOP2017000213 A DO P2017000213A DO 2017000213 A DO2017000213 A DO 2017000213A DO 2017000213 A DO2017000213 A DO 2017000213A DO P2017000213 A DOP2017000213 A DO P2017000213A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- bromodominum
- inhibitors
- bencimidazol
- derivatives
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Compuestos de fórmula (I) y sales de los mismos: en la que R1, R2, R3, R4 son como se han definido en la presente memoria. Se ha encontrado que los Compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas de bromodominio a, por ejemplo, residuos de lisina acetilados y por lo tanto pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide;; y cánceres.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000213A true DOP2017000213A (es) | 2017-10-15 |
Family
ID=53052091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000213A DOP2017000213A (es) | 2015-03-19 | 2017-09-19 | Derivados de bencimidazol como inhibidores de bromodominio |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10442786B2 (es) |
| EP (2) | EP3549939A1 (es) |
| JP (1) | JP6419990B2 (es) |
| KR (1) | KR102072850B1 (es) |
| CN (1) | CN107635989B (es) |
| AR (1) | AR103934A1 (es) |
| AU (1) | AU2016232217B2 (es) |
| BR (1) | BR112017019779B1 (es) |
| CA (1) | CA2979504C (es) |
| CL (1) | CL2017002332A1 (es) |
| CO (1) | CO2017009992A2 (es) |
| CR (1) | CR20170430A (es) |
| CY (1) | CY1121855T1 (es) |
| DK (1) | DK3271349T3 (es) |
| DO (1) | DOP2017000213A (es) |
| EA (1) | EA033594B1 (es) |
| ES (1) | ES2735417T3 (es) |
| GB (1) | GB201504689D0 (es) |
| HR (1) | HRP20191186T1 (es) |
| HU (1) | HUE044414T2 (es) |
| IL (1) | IL254318B (es) |
| LT (1) | LT3271349T (es) |
| MA (2) | MA41778A (es) |
| ME (1) | ME03485B (es) |
| MX (1) | MX2017012023A (es) |
| PE (1) | PE20180032A1 (es) |
| PH (1) | PH12017501620A1 (es) |
| PL (1) | PL3271349T3 (es) |
| PT (1) | PT3271349T (es) |
| RS (1) | RS59056B1 (es) |
| SG (1) | SG11201707356QA (es) |
| SI (1) | SI3271349T1 (es) |
| TW (1) | TW201706257A (es) |
| UY (1) | UY36589A (es) |
| WO (1) | WO2016146738A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| KR20180039117A (ko) | 2015-08-11 | 2018-04-17 | 네오메드 인스티튜트 | 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도 |
| CA2994478C (en) | 2015-08-12 | 2023-10-03 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| TW202332436A (zh) | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| US20210261539A1 (en) * | 2018-02-06 | 2021-08-26 | Shanghai Haihe Pharmaceutical Co., Ltd. | Compound having bet inhibitory activity and preparation method and use therefor |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| CN113874017A (zh) * | 2019-03-15 | 2021-12-31 | 福马治疗股份有限公司 | 抑制环amp-应答元件结合蛋白(creb) |
| US20220259200A1 (en) * | 2019-04-24 | 2022-08-18 | Convergene, Llc | Small molecule bromodomain inhibitors and uses therof |
| WO2020223370A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating schistosoma infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| ES2348829T3 (es) | 2006-03-31 | 2010-12-15 | Janssen Pharmaceutica Nv | Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina. |
| JP2013508461A (ja) * | 2009-10-27 | 2013-03-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EP3010918B1 (en) * | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/en not_active Withdrawn
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/en active Active
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt active IP Right Grant
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko active IP Right Grant
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/en active Application Filing
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh active Active
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/me unknown
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja active Active
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 CA CA2979504A patent/CA2979504C/en active Active
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-01 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000213A (es) | Derivados de bencimidazol como inhibidores de bromodominio | |
| UY37393A (es) | Inhibidores de bromodominios | |
| CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CY1121182T1 (el) | Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| EA201500926A1 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
| CU20160120A7 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| BR112016012781A2 (pt) | Novos métodos | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| BR112016029333A2 (pt) | síntese de compostos de carbamoilpiridona policíclico | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| BR112017019773A2 (pt) | compostos heterocíclicos tricíclicos substituídos | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma | |
| BR112016028081A2 (pt) | Novos compostos como agentes antituberculares | |
| CR20150593A (es) | Potenciador de inhibidores del homólogo de zeste |